Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. - Wikidata - awgldk - TriplyDB

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.

http://www.wikidata.org/entity/Q34875961

about

Prophylactic Measures During Induction for Acute Myeloid Leukemia.Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study 1.Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis on Bronchiolitis Hospitalizations among High-risk Infants.Adherence and outcomes: a systematic review of palivizumab utilization.

P2860

Q30235496-AD26C4DA-3D68-473F-B1FA-17AA9083A13E Q45342359-63E8BEA4-5F5E-4913-97D1-D7CD79A3C230 Q47132154-2E007EBC-35C4-465E-AA30-720A22756079 Q47551236-6501D566-99EF-4CBA-B723-1EAA4F58BF84 Q47582466-2FE005F8-4526-4559-B92B-3EA2E6A690F4

P2860

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.

http://www.wikidata.org/entity/Q34875961

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@ast

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@en

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@nl

type

label

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@ast

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@en

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@nl

prefLabel

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@ast

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@en

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@nl

P1433

Q34875961-4685E7E4-7AF2-441A-A38F-623634AF1FF3

P1476

Q34875961-94BC422D-E297-4C1D-9102-5751DA427D9B

P2093

Q34875961-9BAAFD73-AB70-4AAB-8882-29A380E5451A

Q34875961-BDDF47D8-6C8D-4739-9E84-DFADF23D6BE2

Q34875961-CDEA0736-FAEC-4C4F-AF0D-33CBE13A5D2F

Q34875961-F0E4B867-C689-4512-9DA2-19889DA2CD7B

Q34875961-F4AD3227-D1C1-45BA-A14D-8BF1B5DD4149

Q34875961-FF99E5E4-D225-4321-98EA-2E985547365B

P2860

Q34875961-1FC3CD16-DE94-4153-8E0D-5B7FFA4D3C06

Q34875961-2C73AFD9-DBFF-4181-AAAC-B1A3EF973ACB

Q34875961-4BE3D102-1762-4600-BF01-CED642512D94

Q34875961-5A822354-5C41-48D5-A830-7C139A5EE148

Q34875961-668C7AE9-90AC-4802-B554-B1231B8BDE7D

Q34875961-7709971E-F268-4F50-9C0C-276EA65CC7F9

Q34875961-79123756-B0B6-4235-90F3-5C817F73003F

Q34875961-A8488CF8-1636-473F-93C0-ED0194AFD89C

Q34875961-C6928E7E-F5B6-4EF0-90A2-52DE29C72A8C

Q34875961-F8CC8668-33D2-4BB3-A7EA-6EFE24AA1906

P2888

Q34875961-6CC29538-D202-4958-BBA9-AFF787DDEA6D

P304

Q34875961-BD7461AD-AFA6-4B32-B636-9B3ECD3ACF4A

P31

Q34875961-FEA0F0FE-964C-4A83-B0A8-A70D9F6B46D7

P356

Q34875961-1F0A8E3B-6B06-41B2-96DF-7189A739F71D

P478

Q34875961-868ACC82-8CE8-4225-AC07-B7EC100F53CC

P577

Q34875961-9C2CB85C-998F-4178-A5BD-71733338D363

P5875

Q34875961-92C52B02-B91F-47E6-B50D-844AD6511921

P6179

Q34875961-41D330AB-0B53-41D2-A8DC-A121085E79A0

P698

Q34875961-A401C020-B89A-4BC9-9C1F-A955A352927E

P921

Q34875961-F7C595CF-B3FF-422E-BE5C-986D9E4AE94A

P932

Q34875961-45B2A625-724D-4301-B79B-E782E45DA00A

P356

1471-2431-14-261

P1433

P1476

Partial palivizumab prophylaxi ...... retrospective cohort analysis.

@en

P2093

Anthony S Masaquel

http://www.w3.org/2001/XMLSchema#string

David M Smith

http://www.w3.org/2001/XMLSchema#string

Leonard B Weiner

http://www.w3.org/2001/XMLSchema#string

Leonard R Krilov

http://www.w3.org/2001/XMLSchema#string

Parthiv J Mahadevia

http://www.w3.org/2001/XMLSchema#string

Sally W Wade

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Hospitalization for respiratory syncytial virus among California infants: disparities related to race, insurance, and geography.

Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.

Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Effectiveness of palivizumab prophylaxis in infants and children in Florida

P2888

1471-2431-14-261

P304

261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2431-14-261

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266950171

http://www.w3.org/2001/XMLSchema#string

P6179

1004780232

http://www.w3.org/2001/XMLSchema#string

P698

25308481

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

4287588

http://www.w3.org/2001/XMLSchema#string